Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 7:59 p.m.

    📋 Gemini Therapeutics Inc. (the company became a subdivision of the company Disc Medicine (NASDAQ : IRON)) (GMTX) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:37:00

    Event Type: Clinical Trial Update

    Event Details:

    Gemini Therapeutics Inc. (the company became a subdivision of the company Disc Medicine (NASDAQ : IRON)) (GMTX) Announces Clinical Trial Update Gemini Therapeutics Inc. (the company became a subdivision of the company Disc Medicine (NASDAQ : IRON)) (GMTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: expected
    • Clinical Stage: Phase 2, Phase 2 study
    • Collaboration: SCD
      • Bitopertin NDA submitted and accepted under the accelerated approval pathway with priority review
      • Bitopertin awarded the Commissioner’s National Priority Voucher (CNPV), a pilot program designed to accelerate the NDA review period to 1
      • Transition to commercial
        • expected in H2 2026
        • expected by early 2027
        • targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com. Disc Cautionary Statement Regarding Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (Gemini Therapeutics Inc. (the company became a subdivision of the company Disc Medicine (NASDAQ : IRON))):

    Product Type Development Stage Therapeutic Area Source
    DISC-3405 DRUG Phase PHASE2 Polycythemia Vera (PV) ClinicalTrials.gov
    DISC-0974 DRUG Phase PHASE2 Inflammatory Bowel Disease (IBD) ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Inflammatory Bowel Disease (IBD) ClinicalTrials.gov
    DISC-1459 DRUG Phase PHASE3 Erythropoietic Protoporphyria (EPP) ClinicalTrials.gov
    GEM103 BIOLOGICAL Phase PHASE1 Dry Age-related Macular Degeneration ClinicalTrials.gov
    Sham DRUG Phase PHASE2 Neovascular Age-related Macular Degeneration ClinicalTrials.gov
    Aflibercept DRUG Phase PHASE2 Neovascular Age-related Macular Degeneration ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Gemini Therapeutics Inc. (the company became a subdivision of the company Disc Medicine (NASDAQ : IRON))
    • Ticker Symbol: GMTX

Search

News categories